PDCD1 and Miyoshi myopathy: The purpose of this study was to explore features extracted on baseline CT and post-treatment (delta-radiomics features) as predictors of OS and PFS in patients with MM treated with the PD-1 inhibitor Nivolumab, and its ability to act as a novel imaging biomarker for predicting survival.